RxDoctor Payments Data

Roger Garcia, DO

Addiction Medicine · Columbus, OHNPI 1366655656

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by USWM, LLC at 26.4% of the total.

$2,804in general payments, 2019–2025

Across 111 payments — averaging $25.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • USWM, LLC$741
  • Braeburn Inc.$737
  • Indivior Inc.$399
  • Alkermes, Inc.$364
  • MDD US Operations, LLC$288
  • Orexo US, Inc.$192
  • plus $82 from 3 others

What the payments were for

  • Food & beverage$2,78399%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,804 in reported general payments places this provider in the 85th percentile of 98 addiction medicine providers in Ohio.

See all addiction medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$26,584
Medicare patients
14
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl106$9,829
ZubsolvBuprenorphine Hcl/Naloxone Hcl27$7,627
Testosterone Cypionate12$447
Estradiol (Twice Weekly)Estradiol11$406
Buprenorphine Hcl11$371
ProgesteroneProgesterone, Micronized12$272
Ondansetron OdtOndansetron12$91
Clonazepam21$88
Carisoprodol15$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl$38$10,200117 claims
Orexo US, Inc.Zubsolv$192$7,62727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 98 addiction medicine providers in Ohio.

Other addiction medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →